Netilmicin 200 mg twice a day for adult patients with life-threatening infections. A preliminary report.
The efficacy and toxicity of netilmicin was assessed in 15 patients with life-threatening infections, including six with septicaemia. Fourteen patients were cured with no recurrence of infection. The initial dosage of netilmicin was 200 mg twice a day (2.3-4.0 mg/kg/dose), but subsequent adjustment of dosage was made according to the results of serum assay, either to avoid accumulation or to improve therapeutic response. Probable nephrotoxicity occurred in only one patient and there was no evidence of ototoxicity in the twelve patients who could be assessed.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D003404:Creatinine / Q000097:blood; D004341:Drug Evaluation; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage*; D006309:Hearing / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009428:Netilmicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D011552:Pseudomonas Infections / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy
D005839:Gentamicins; D009428:Netilmicin; D003404:Creatinine